 |
發表人 |
內容 |
Walleyenads
訪客
|
發表於:
星期四 七月 24, 2008 7:31 am |
  |
ROCKVILLE, Md., July 14, 2008--Genentech, Inc. alert to healthcdare professionals of storys of disparate cases of mciroangiopathic hemolytic anemia (MAHA) in patients with cialis ohne rezept tumors receiving Avastin in party with sunitinib maalte. Avastin is not approved for use in solution with sunitinib malate and this party is not recommended. Twenty-five patients were enrolled in a time I portion-escalation read combining Avastin and sunitinib malate. The read consisted of
3 cohorts using a regular portion of Avastin at 10mg/kg/IV every 2 weeks and escalating dispenses of sunitinib that comprised 25, 37.5, and 50 mg orally every day premised in a 4 weeks on/ 2 weeks off schedule. Five of 12 patients at the highest sunitinib dosage knock down exhibited laboratory findings accordance with MAHA. Two of these cases were considered austere with show of thrombocytopenia, anemia, reticulocytosis, reductions in serum haptoglobin, schistocytes on tangential taint,
demure increases in serum creatinine plains, and Draconic hypertension, reversible rear leukoencephalopathy syndrome, and proteinuria. The findings in these two cases were reversible within three weeks upon discontinuation of both drugs without additional interventions. Healthcare professionals should blast cases of MAHA or any sober adverse events suspected to be associated with the use of Avastin. |
|
|
|
 |
|
|
下一篇主題
上一篇主題
您 可以 在這個版面發表文章 您 可以 在這個版面回覆文章 您 無法 在這個版面編輯文章 您 無法 在這個版面刪除文章 您 無法 在這個版面進行投票
|
|